Neutralization Assays: How Blocking Antibodies Work and How to Test Them

Neutralization assays measure the ability of an antibody to block a biological function — typically the ability of a virus to infect cells, a ligand to bind its receptor, or a cytokine to activate a signaling pathway. Unlike standard binding assays (ELISA, WB), neutralization assays provide functional evidence that an antibody not only binds its target but actively inhibits its biological activity.

This makes neutralization assays essential tools in infectious disease research, immuno-oncology, vaccine development, and therapeutic antibody characterization. This guide covers the most common formats and provides practical advice for selecting antibodies and optimizing your assay.

1. What Does Neutralization Mean?

In immunology, neutralization refers to the ability of an antibody to abolish or reduce the biological activity of its target molecule. The antibody achieves this by binding to a functionally critical site on the target — for example, the receptor-binding domain (RBD) of a viral spike protein, the active site of a toxin, or the receptor-binding interface of a cytokine — physically preventing the target from engaging its natural binding partner.

Not all antibodies that bind a target can neutralize it. An antibody may bind a non-functional epitope (e.g., a region on the viral capsid that is distant from the receptor-binding site), providing excellent ELISA or WB signal but no functional blocking. This is why neutralization must be tested with a functional assay, not inferred from binding data alone. For more on the distinction between binding specificity and functional activity, see our Antibody Specificity and Validation guide.

2. Common Neutralization Assay Formats

3. Antibody Selection for Neutralization Studies

Not every antibody against a target will neutralize. When selecting antibodies for neutralization experiments, consider:

For applications requiring the smallest possible binding fragment, VHH nanobodies offer unique advantages in neutralization assays: their small size (~15 kDa) enables access to cryptic epitopes such as receptor-binding pockets and viral canyon regions that conventional IgG antibodies cannot reach.

4. Optimizing Dose-Response Curves

Neutralization assays are quantitative: the goal is to determine the IC₅₀ (the antibody concentration that inhibits 50% of the biological activity) or, for viral neutralization, the NT₅₀ (the serum dilution that reduces infection by 50%). Proper dose-response optimization is critical for reproducible results.

1. Use a wide concentration range: Start with at least an 8-point, 3-fold or 4-fold serial dilution spanning 3–4 logs (e.g., 10 µg/mL down to 0.001 µg/mL). This ensures you capture the full sigmoidal curve from 0% to 100% inhibition. For guidance on serial dilution strategies, see our Antibody Dilution Optimization guide.

2. Include proper controls: Virus/ligand-only control (0% inhibition baseline), cells-only control (maximum viability / minimum signal), and an isotype control antibody at the highest concentration (confirms neutralization is target-specific, not due to IgG itself).

3. Pre-incubate antibody with target: For virus neutralization, incubate the antibody-virus mixture for 1 h at 37°C before adding to cells. This allows antibody-antigen binding to reach equilibrium. For receptor-blocking ELISA, pre-incubate antibody with soluble ligand before adding to the coated receptor plate.

4. Run in duplicate or triplicate: Biological variability in cell-based assays requires replicates. Report IC₅₀ with 95% confidence intervals.

5. Fit the curve properly: Use a 4-parameter logistic (4PL) regression to fit the sigmoidal dose-response curve. Most graphing software (GraphPad Prism, R) supports 4PL fitting natively. The IC₅₀ is derived from the midpoint of the fitted curve.

To complement IC₅₀ data with binding kinetics (on-rate, off-rate, K_D), label-free methods such as SPR and BLI can provide mechanistic insight into why certain antibodies neutralize more potently than others.

5. Frequently Asked Questions

Q: What is the difference between a neutralizing antibody and a non-neutralizing antibody?

Both bind the target antigen, but only a neutralizing antibody blocks the target's biological function. A non-neutralizing antibody may bind a region of the protein that is not involved in receptor binding or enzymatic activity. Non-neutralizing antibodies are still useful for detection (ELISA, WB, IHC) and may contribute to Fc-mediated immune responses (in vivo ADCC/phagocytosis), but they cannot directly inhibit the target's functional activity.

Q: Can I use a polyclonal antibody for neutralization?

Yes, and polyclonal sera (e.g., convalescent serum, post-vaccination serum) are routinely tested in viral neutralization assays to assess the overall neutralizing response. However, because polyclonal antibodies contain a mixture of neutralizing and non-neutralizing antibodies, the IC₅₀ reflects the combined activity of the mixture, not a single molecular species. For mechanistic studies or epitope-level analysis, monoclonal antibodies are preferred. For a deeper comparison, see our Monoclonal vs. Polyclonal Antibodies guide.

Q: What is a surrogate virus neutralization test (sVNT)?

The sVNT is a competitive ELISA-based assay that measures the ability of antibodies to block the binding of a viral protein (e.g., SARS-CoV-2 RBD) to its host receptor (e.g., ACE2) in a plate-based format. It does not require live virus, pseudovirus, or cell culture — making it the simplest and fastest neutralization assay format. sVNTs correlate well with PRNT and pseudovirus assays for many virus-receptor systems and are widely used for seroprevalence screening and vaccine monitoring. For step-by-step ELISA setup, see our ELISA Protocol Guide.

Q: How do I distinguish between steric blocking and allosteric inhibition?

Steric blocking occurs when the antibody physically occupies the receptor-binding site, preventing the ligand from accessing it. Allosteric inhibition occurs when the antibody binds a site distant from the active site but induces a conformational change that reduces activity. Competitive binding assays (e.g., receptor-blocking ELISA) primarily detect steric blocking. To distinguish between mechanisms, epitope mapping (by mutagenesis or hydrogen-deuterium exchange mass spectrometry) combined with structural studies (cryo-EM, X-ray crystallography) is typically required.

Q: What is a good IC₅₀ for a neutralizing antibody?

It depends on the context. For therapeutic antibody candidates, IC₅₀ values in the low nanomolar range (1–100 ng/mL) are considered potent. For research-grade neutralizing antibodies used as positive controls or tool compounds, IC₅₀ values up to 1–10 µg/mL are typically acceptable. Research biosimilar antibodies are commonly used as reference standards in neutralization assays to benchmark novel candidates. Always compare IC₅₀ values obtained under identical assay conditions, as they vary significantly between assay formats, cell lines, and virus strains.

References

1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8

2. Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680-686. doi: 10.1080/22221751.2020.1743767

3. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z

This article is provided for educational purposes only. For technical support, contact order@abinscience.com.